Blog
RSS FeedPosted by Michael Wonder on 01 Jan 2025
Tarlatamab approved to treat adult patients with small cell lung cancer
31 December 2024 - The MHRA has today approved the medicine tarlatamab (Imdyllytra) to treat adult patients with small cell lung ...
Posted by Michael Wonder on 01 Jan 2025
Sotatercept approved to treat adult patients with pulmonary arterial hypertension
27 December 2024 - The MHRA has approved the medicine sotatercept (Winrevair) to treat pulmonary arterial hypertension. ...
Posted by Michael Wonder on 28 Dec 2024
What price is society willing to pay for new drugs?
12 December 2024 - The purpose of England's NHS is to improve the health and wellbeing of the nation through provision ...
Posted by Michael Wonder on 23 Dec 2024
Over 1,000 people with advanced breast cancer set to benefit from new once a day tablet
19 December 2024 - We’ve issued final draft guidance recommending a new once a day tablet that is set to benefit ...
Posted by Michael Wonder on 22 Dec 2024
NICE recommends new treatment to prevent and reduce hearing loss in people being treated for cancer
20 December 2024 - For the first time, NICE has recommended an innovative new treatment to help stop babies, children and ...
Posted by Michael Wonder on 22 Dec 2024
Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy
20 December 2024 - The MHRA has today granted a conditional marketing authorisation for the medicine givinostat (Duvyzat) to treat Duchenne ...
Posted by Michael Wonder on 18 Dec 2024
Ublituximab for the treatment of patients with relapsing multiple sclerosis
18 December 2024 - NICE has published final evidence-based recommendations on the use of ublituximab (Briumvi) for the treatment of ...
Posted by Michael Wonder on 18 Dec 2024
What is NICE’s severity modifier?
15 December 2024 - A guide to the severity modifier and how it is leading to more positive recommendations overall from ...
Posted by Michael Wonder on 16 Dec 2024
Should NICE’s cost effectiveness thresholds change?
13 December 2024 - We explore the on-going debate around NICE’s cost effectiveness thresholds and what the future holds. ...
Posted by Michael Wonder on 13 Dec 2024
UK MHRA grants innovation passport designation to ILiAD Biotechnologies BPZE1 next generation intranasal pertussis vaccine
4 December 2024 - ILiAD Biotechnologies today announced that the UK MHRA has granted Innovation Passport designation to BPZE1, the leading ...
Posted by Michael Wonder on 12 Dec 2024
Toripalimab in combination with chemotherapy for the first-line treatment of patients with advanced oesophageal squamous cell cancer
11 December 2024 - NICE is unable to make a recommendation on the use in the NHS of toripalimab (Loqtorzi) in ...
Posted by Michael Wonder on 10 Dec 2024
New price deal paves way for NICE approval of treatment for rare genetic condition
10 December 2024 - A new treatment for Duchenne muscular dystrophy is set to be available to around 1,700 people in ...
Posted by Michael Wonder on 09 Dec 2024
Cladribine for the treatment of patients with relapsing multiple sclerosis
6 December 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 08 Dec 2024
Ruxolitinib phosphate for the treatment of patients with acute graft versus host disease that responds inadequately to corticosteroids
6 December 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 06 Dec 2024
Molnupiravir for the treatment of patients with COVID-19 infection
26 November 2024 - NICE has published further draft guidance on the use of molnupiravir (Lagevrio) in the NHS in ...